August 2011 references and further reading

Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation 2010; 121:586-613. Bambs C, Kip KE, Dinga A, Mulukutla SR, Aiyer AN, Reis SE. Low prevalence of "ideal cardiovascular health" in a community-based population: the heart strategies concentrating on risk evaluation (Heart SCORE) study. Circulation 2011; 123:850-7. Folsom AR, Yatsuya H, Nettleton JA, Lutsey PL, Cushman M, Rosamond WD. Community prevalence of ideal cardiovascular health, by the american heart association definition, and relationship with cardiovascular disease incidence. Journal of the American College of Cardiology 2011; 57:1690-6. (Locked) More »

Aiming for ideal improves heart health

The American Heart Association hopes that its definition of ideal cardiovascular health will encourage people to strive to be healthier. The AHA defines "ideal cardiovascular health" as the combination of four healthy behaviors and three health measurements. Ideal cardiovascular health is an excellent benchmark and a goal to strive for.  Aim for what's possible instead of what's perfect. If you don't currently qualify for any of the seven ideal categories, working to achieve one of them will improve your odds of avoiding a heart attack, stroke, heart failure, or other cardiovascular event. (Locked) More »

Trial clouds use of niacin with a statin

A large clinical trial dubbed AIM-HIGH was designed to gauge whether adding a prescription form of niacin (Niaspan) to a cholesterol-lowering statin makes sense for people with low HDL. When the trial's safety panel analyzed preliminary results, niacin didn't offer any additional benefit. A small and highly unexpected difference in the rate of ischemic (clot-caused) stroke — 1.6% in the niacin group versus 0.7% in the statin-only group — contributed to the panel's decision to halt AIM-HIGH early. (Locked) More »

Update on aspirin

For people who have not had a heart attack, the question of whether or not to take a daily aspirin is a matter of weighing potential benefits against potential harm. (Locked) More »

No connection between ARBs and cancer

The Food and Drug Administration has concluded that angiotensin-receptor blocker medications used to treat high blood pressure do not increase the risk of developing lung cancer. (Locked) More »